Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Hemogenyx Pharmaceuticals Llc

Clinical trials sponsored by Hemogenyx Pharmaceuticals Llc, explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Engineered t cells target FLT3 in Hard-to-Treat leukemia Results expected Jan 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1

Engineered t cells target FLT3 in Hard-to-Treat leukemia

Cure Recruiting now

Researchers are testing a new cell therapy called anti-FLT3 CAR-T (HG-CT-1) in adults and children with acute myeloid leukemia (AML) that has come back or stopped responding to standard treatment. The study is a Phase 1 dose-escalation trial, meaning its first goal is to find out…

Phase 1 • Sponsor: Hemogenyx Pharmaceuticals LLC • Aim: Cure

Last updated Sep 19, 2026 00:00 UTC